# | ||||
---|---|---|---|---|
1 | FIGHTINGDRUGFAILURE Priorities and Standards in Pharmacogenomic Research: Opportunities for a Safer and More Efficient Pharmacotherapy | 2009 | 3˙187˙750.00 | 3˙187˙750.00 |
L'Ente robert bosch gesellschaft fur medizinische forschung mbh partecipato anche in questi progetti.